Welcome to our dedicated page for iBio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on iBio stock.
iBio, Inc. (symbol: IBIO) is a specialized contract development and manufacturing organization (CDMO) that facilitates the journey from early product selection to market launch. Situated within the healthcare sector, iBio is renowned for its plant-based protein expression technologies, which are pivotal in developing vaccines, therapeutic proteins, and biopharmaceutical products.
The company operates through two primary segments: Biopharmaceuticals and Bioprocessing. iBio's Biopharmaceuticals segment focuses on the development and commercialization of product candidates aimed at addressing critical health issues such as fibrotic diseases, cancers, and infectious diseases. The Bioprocessing segment, meanwhile, involves comprehensive manufacturing and regulatory support services offered through iBio CDMO.
iBio's technology platform and state-of-the-art facilities are designed to expedite development processes, providing significant time and cost advantages over traditional approaches. The company boasts a team of skilled protein scientists, microbiologists, manufacturing experts, and regulatory professionals committed to delivering seamless scale-up from preclinical to commercial production.
Recent achievements include advancements in biotherapeutics and diagnostic products, showcasing iBio's capability to innovate and respond to global health challenges effectively. The company also maintains strategic partnerships that bolster its research and development efforts, ensuring consistent progress in the healthcare landscape.
With its focus on rapid manufacturing support and regulatory compliance, iBio stands out as a reliable partner for clients seeking efficient pathways to clinical and commercial success.
iBio, a biotech company, has appointed Dr. Linda Armstrong to its Board of Directors and the newly established Science & Technology Committee. Dr. Armstrong brings over 20 years of expertise in respiratory diseases, having previously served as Global Head of Respiratory Development at Novartis. Her experience in biologics development is expected to enhance iBio's respiratory disease portfolio, including COVID-19 therapeutic candidates and IBIO-100 for idiopathic pulmonary fibrosis. iBio aims to leverage her insights to advance its product development initiatives.
iBio, a biotech innovator, reported record revenues of over $1.1 million in Q4 and total revenues of approximately $1.6 million for the fiscal year ended June 30, 2020. This reflects a decrease from $2.0 million in FY 2019, mainly due to timing in service revenues. However, revenue from third-party customers increased by 118%. Operating expenses fell to $15.6 million from $17.8 million, while net loss narrowed to $16.4 million or $0.61 per share. iBio's cash position strengthened, increasing to $83.1 million by September 30, 2020.
iBio, Inc. (NYSE AMERICAN:IBIO) has announced it regained compliance with NYSE American listing standards as of October 1, 2020. This follows the company's resolution of a previous deficiency related to market capitalization. CEO Tom Isett emphasized that the company’s new strategic plan has strengthened its financial position and value drivers. iBio aims to leverage its proprietary technologies, including the FastPharming® System, to develop biological medicines for respiratory diseases, including COVID-19.
iBio has signed a Master Services Agreement with Safi Biosolutions to evaluate the use of its FastPharming System in producing proteins for blood cell therapies. This collaboration aims to enhance the bioprocessing of red blood cells and neutrophil therapies, which are critical for trauma and chemotherapy recovery. Additionally, iBio will invest $1.5 million in Safi via a convertible promissory note, boosting its role in innovative blood products development.
iBio has announced that its candidate IBIO-201, a LicKM™-subunit vaccine, showed superior efficacy in inducing anti-spike neutralizing antibodies in preclinical studies compared to IBIO-200. The company plans to advance IBIO-201 into toxicity studies and continue evaluating IBIO-200 as part of its COVID-19 vaccine development program. Collaboration with IDRI and the Texas A&M University System is ongoing to further characterize and test IBIO-201. iBio has capabilities for clinical manufacturing at its facility in Texas.
iBio, Inc. (NYSE AMERICAN: IBIO) announced an exclusive worldwide license with Planet Biotechnology for the development of ACE2-Fc, a therapeutic candidate targeting COVID-19. The ACE2-Fc protein acts as a decoy to block SARS-CoV-2 from infecting cells. iBio aims to leverage its FastPharming® System for rapid product development and has the capability to manufacture at clinical and commercial scales. Planet is eligible for milestone payments as development progresses, highlighting the potential collaboration in addressing the pandemic.
iBio Inc. (NYSE AMERICAN: IBIO) provided a promising update on its COVID-19 vaccine candidate, IBIO-201. Preclinical studies demonstrated its ability to generate immune responses against SARS-CoV-2, with increasing antibody titers observed over 42 days. The company is collaborating with Texas A&M University System to conduct additional testing focused on neutralizing titers and immune profiling. iBio highlighted its capability to advance vaccine candidates rapidly, leveraging its FastPharming Facility for scale-up production.
iBio, Inc. (NYSE AMERICAN:IBIO) will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2020. This addition signals significant progress in the company’s journey to enhance shareholder value. CEO Tom Isett highlighted recent achievements, including the launch of the FastGlycaneering Development Service™ and collaborations for a bio-better rituximab. Furthermore, iBio is advancing COVID-19 vaccine candidates, with preclinical data expected in Q3-2020, showcasing potential future milestones for the company.
iBio has been selected by IBM Watson Health to receive 18 months of complimentary use of the IBM Clinical Development (ICD) solution, aimed at facilitating the company's COVID-19 vaccine trials. This recognition highlights iBio's potential in vaccine development, among hundreds of applicants. Data from preclinical studies of the COVID-19 vaccine candidates IBIO-200 and IBIO-201 is expected in Q3-2020. The partnership is anticipated to accelerate clinical trial processes and enhance data management efficiency.
iBio announced the initiation of preclinical immunization studies for its second COVID-19 vaccine, IBIO-201, featuring a subunit vaccine combining SARS-CoV-2 spike protein antigens and the proprietary LicKM booster technology. This development could enhance immune response and manufacturing capacity. iBio's plant-based FastPharming System™ facilitates scalable production, potentially yielding hundreds of millions of doses. The vaccine's efficacy is backed by prior research, indicating the promise of LicKM technology in achieving prolonged immunity.
FAQ
What is the current stock price of iBio (IBIO)?
What is the market cap of iBio (IBIO)?
What does iBio, Inc. specialize in?
What are the main segments iBio operates in?
What services does iBio offer?
Who comprises iBio’s team?
What are the key areas iBio's products target?
How does iBio's technology platform benefit clients?
What recent achievements has iBio made?
What is iBio CDMO?
Does iBio collaborate with other organizations?
How can I contact iBio for investor or media relations?
